AI Article Synopsis
- * A case report details a 40-year-old woman who was treated with trastuzumab following acute heart failure caused by postoperative Takotsubo cardiomyopathy, with careful monitoring for one year.
- * The patient showed no heart-related symptoms during follow-up, indicating that trastuzumab can be used safely in similar patients despite potential risks.
Article Abstract
Background: Trastuzumab is a humanized monoclonal antibody used for the treatment of HER2-positive breast cancer. Cardiotoxicity is a well-known adverse event of trastuzumab use but little has been documented regarding its use in patients with a history of cardiac disease.
Case Report: We describe a case in which trastuzumab treatment was administered to a 40-year-old female patient with early breast cancer after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. After one year of follow-up with close monitoring by echocardiography, there have been no heart-related symptoms. Additional surgery was performed because of positive resection margins at first surgery, without complications, despite the risk of recurrence of Takotsubo cardiomyopathy.
Conclusion: Trastuzumab can be safely administered after acute heart failure secondary to postoperative Takotsubo cardiomyopathy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!